Loading
A phase 3 trial testing Precemtabart tocentecan in colorectal cancer, now recruiting.
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) is a phase 3 interventional study registered as NCT07549412, led by EMD Serono Research & Development Institute with Merck KGaA, Darmstadt, Germany, and recruiting on the registry. Official title: A Randomised, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03). Planned enrolment is 1020 participants (estimated). The study started in 2026-05-06 and primary completion is expected in 2029-10-16. No results have been posted on ClinicalTrials.gov.